Global Regulatory Affairs
United States of America
Ashley Hall is Vice President of Global Regulatory Affairs. Prior to joining Esperion, Ashley was Global Regulatory Lead for Cardiovascular at Amgen, and oversaw the regulatory strategy and global filings for the evolocumab program leading to the world’s first approval of a PCSK9 inhibitor for cholesterol lowering. Previously, Ashley was Vice President of Regulatory Affairs at Micromet, which was acquired by Amgen in March of 2012. Prior to joining Micromet, she was Vice President of Regulatory and Clinical Affairs at RevoGenex, and before that, Director of World Wide Regulatory Affairs with the oncology team at MedImmune. Ashley held various roles of increasing responsibility in global Regulatory Affairs at Abraxis BioScience and at La Jolla Pharmaceutical Company. Ashley has also worked in Global Regulatory Policy at Amgen and as a policy intern for Francis Collins at the National Human Genome Institute. Ashley earned her Juris Doctorate at the University of San Diego School of Law and her Bachelors of Science in Biochemistry and Cell Biology at the University of California San Diego.
Regulatory and Clinical Affairs,Biochemistry and Cell Biology